Impedimed device gets breakthrough designation for kidney failure
The company’s bioimpedance spectroscopy device would be used to measure how much fluid should be removed from a patient during dialysis.
Australian device maker strikes partnership with the U.S. Oncology Network
Impedimed, which is headquartered in Australia, makes a tool for early detection of lymphedema in cancer patients.
presented by
5 Major Trends Emerging in Healthcare Benefits in 2025
Employees who enjoy their benefits are more inclined to stay with their company. A 2025 Marsh McLennan Agency report said 73% of employees would remain if plan options were better.